No quarterly revenue total was found in Alto Neuroscience, Inc.'s SEC filings.
Alto Neuroscience, Inc. (ANRO) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$19.8 million. As of Jun 30, 2026 it held $243.7 million in cash and investments and $20.8 million in total debt.
Revenue
—
Net income
$-27.64M
-56.1% vs year-ago quarter
Operating cash flow
$-19.76M
-43.4% vs year-ago quarter
Free cash flow
$-19.76M
-43.4% vs year-ago quarter
EPS
$-0.65
+0.0% vs year-ago quarter
Dividend per share
None
Shares outstanding
39.24M
+44.9% vs year-ago quarter
Net cash
$222.90M
Q2 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ANRO (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Mountain View, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1999480
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$29.1M | -$27.1M | -$17.1M | -$15.0M | -$18.7M |
| Net income | -$27.6M | -$26.2M | -$16.2M | -$14.2M | -$17.7M |
| Diluted EPS | -$0.65 | -$0.80 | -$0.47 | -$0.52 | -$0.65 |
| Operating cash flow | -$19.8M | -$27.1M | -$11.5M | -$9.9M | -$13.8M |
| Free cash flow | -$19.8M | -$27.6M | -$11.5M | -$9.9M | -$13.8M |
| Total assets | $254.1M | $276.3M | $184.7M | $147.0M | $157.9M |
| Total liabilities | $34.8M | $32.9M | $33.5M | $35.4M | $34.5M |
| Stockholders' equity | $219.2M | $243.4M | $151.1M | $111.6M | $123.4M |
| Cash and investments | $243.7M | $263.8M | $176.5M | $137.8M | $147.6M |
| Total debt | $20.8M | $20.9M | $21.7M | $25.4M | $25.3M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change
|
Aug 27, 2026 | Aug 26, 2026 |
| 10-Q | Quarterly report | Aug 12, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 12, 2026 | Aug 12, 2026 |
| 8-K |
Current report
Material agreement
|
Jul 14, 2026 | Jul 13, 2026 |
| 8-K |
Current report
Results of operations, Other events
|
Jul 13, 2026 | Jul 13, 2026 |
| 8-K |
Current report
Officer or director change
|
May 28, 2026 | May 27, 2026 |
All 196 Alto Neuroscience, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.